Navigation Links
Royalty Pharma Acquires a Portion of Northwestern University's Royalty Interest in Lyrica(R) for $700 Million

NEW YORK, Dec. 18 /PRNewswire/ -- Royalty Pharma and Northwestern University announced today that Northwestern has sold a portion of its worldwide royalty interest in Lyrica(R) to Royalty Pharma for $700 million in cash.

(Logo: )

A portion of the payment to Northwestern will go to the researchers who were responsible for the chemical compound that serves as the basis for Lyrica(R).

"We're very pleased to have reached this agreement with Royalty Pharma," said Eugene S. Sunshine, Northwestern's senior vice president for business and finance. "Beginning with the original research done at Northwestern, the development of Lyrica(R) has brought relief to thousands of patients worldwide. This exemplifies the type of cutting-edge research that is occurring at Northwestern."

"We are happy to add this royalty on an important pain therapy to our diversified portfolio of royalties on leading biopharmaceutical products," said Pablo Legorreta, Chief Executive Officer of Royalty Pharma. "This transaction exemplifies our commitment to providing leading institutions such as Northwestern with funds that will allow them to continue to pursue their academic and research initiatives. We are confident that these funds will result in continued innovations and advances that will better people's lives."

Lyrica(R) is used to treat nerve pain associated with diabetes and shingles and to help manage pain caused by fibromyalgia. It is manufactured by Pfizer, Inc., the world's largest research-based biomedical and pharmaceutical company. Lyrica(R) is based on the chemical compound pregabalin, first synthesized at Northwestern.

The net proceeds from the partial sale of royalty rights will be placed in the University's endowment, Sunshine said. As part of the endowment, the proceeds will be used in accordance with federal law to help support financial aid for undergraduate and graduate students; startup costs for the University's research efforts; construction of new buildings and laboratories and improvements to existing facilities; and for other purposes.

"Essentially, we are converting a potential stream of future royalty revenues from Lyrica into an immediate cash payment," Sunshine explained. "We continue to believe strongly in Lyrica's potential and Northwestern retains a large portion of those royalty rights, but by doing this, we are diversifying the University's investments."

The percentage of the University's interest in the royalty payments that was sold today is not being disclosed.

Morgan Stanley is acting as structuring advisor and Covington & Burling LLP is acting as the legal advisor to Northwestern University for this sale. Goodwin Procter LLP is acting as legal advisor to Royalty Pharma for this sale.

About Northwestern University

Founded in 1851, Northwestern University is a leading private research and teaching university with an enrollment of approximately 8,000 full-time undergraduate students and approximately 7,000 full-time graduate and professional students on campuses in Evanston and Chicago, Illinois.

Northwestern combines innovative teaching and pioneering research in a highly collaborative environment that transcends traditional academic boundaries. Northwestern provides students and faculty exceptional opportunities for intellectual, personal and professional growth in a setting enhanced by the richness of Chicago.

For more information, go to:

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property -- principally royalty interests in marketed and late stage biopharmaceutical products with a market value of over $4.5 billion. Royalty Pharma currently owns a diversified portfolio of royalty interests in several high-quality blockbuster biopharmaceutical products, including Abbott's Humira(R), J&J/Centocor's Remicade(R), Amgen's Neupogen(R) and Neulasta(R), Genentech's Rituxan(R), Gilead's Emtriva(R), Truvada(R) and Atripla(R), and Celgene's Thalomid(R).

The company has a ten year history of providing value to holders of royalty interests, including its $650 million purchase of the Remicade(R) royalty from New York University, its $700 million purchase of the Humira(R) royalty from AstraZeneca plc, its joint $525 million acquisition with Gilead Sciences of Emory University's emtricitabine royalty interest and its acquisitions of approximately 80% of Memorial Sloan Kettering's U.S. and international royalty interests in Neupogen(R) and Neulasta(R) for over $400 million.
More information on Royalty Pharma is available at


Northwestern University Royalty Pharma

Alan Cubbage Pablo Legorreta, Chief Executive

Department of University Relations Officer

847-491-4886 Susannah Gray, Executive Vice President and Chief Financial


Alexander Kwit, Executive Vice

President and General Counsel

Mike Herman, Vice President,



SOURCE Royalty Pharma
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Unilens Vision Reports Record First Quarter Earnings and Royalty Income
2. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
Post Your Comments:
(Date:11/27/2015)... ... 28, 2015 , ... There is only one major question facing all law ... , This question has not been an easy question to answer. Especially when the ... the younger workforce don’t share the same discipline around working long hours. , ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... According to ... out by the University of Toronto and the University of British Columbia suggested that ... for head injuries. The article explains that part of the reason for the controversial ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... affecting the health care in America. As people age, more care is needed, ... costs are rising, and medical professionals are being overworked. The forgotten part of ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... safe and convenient way to dispense prescription medications at home, so he invented ... way to monitor and dispense prescription medications. In doing so, it could help ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just ... is offering customers 10% off of their purchase of lice treatment product. In addition, ... price. According to a company spokesperson. “Finding lice is a sure way to ruin ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)... 2015 CIVCO Medical Solutions will demonstrate ... Radiological Society of North America ... November 29 – December 4, 2015. The ... customers unrivaled versatility, enhanced user experience and deliver ... --> --> ...
(Date:11/27/2015)... YORK , November 27, 2015 ... system is set to go online. The potential to ... processes is vast and far from fully exploited as ... to patient health records, either via mobile tablet or ... ) --> ) --> ...
(Date:11/27/2015)... , Nov. 27, 2015 Research and Markets ... "Global Intrauterine Devices Market 2015-2019" report to ... --> In this report, the author the present ... market for 2015-2019. To calculate the market size, the ... type of products: Hormonal IUDs and copper IUDs. The ...
Breaking Medicine Technology: